Literature DB >> 20001637

Cardiac complications in thalassemia major.

John C Wood1.   

Abstract

Thalassemia major is characterized by chronic ineffective erythropoiesis and anemia as its primary problems. These, in turn, produce physiologic adaptations in the cardiovascular system as well as pathologic/iatrogenic processes such as iron overload, splenectomy, nutritional deficiencies, chronic oxidative stress, and lung disease. This article discusses the pathophysiology of thalassemia as it relates to the cardiovascular system, the mechanisms and monitoring of iron cardiomyopathy, pulmonary hypertension, and vascular aging in thalassemia patients.

Entities:  

Mesh:

Year:  2009        PMID: 20001637      PMCID: PMC2906452          DOI: 10.3109/03630260903347526

Source DB:  PubMed          Journal:  Hemoglobin        ISSN: 0363-0269            Impact factor:   0.849


  7 in total

1.  Pulmonary hypertension in thalassemia: association with platelet activation and hypercoagulable state.

Authors:  Sylvia T Singer; Frans A Kuypers; Lori Styles; Elliott P Vichinsky; Drucella Foote; Howard Rosenfeld
Journal:  Am J Hematol       Date:  2006-09       Impact factor: 10.047

2.  Normalized left ventricular volumes and function in thalassemia major patients with normal myocardial iron.

Authors:  Mark A Westwood; Lisa J Anderson; Alicia M Maceira; Farrukh T Shah; Emma Prescott; John B Porter; Beatrix Wonke; J Malcolm Walker; Dudley J Pennell
Journal:  J Magn Reson Imaging       Date:  2007-06       Impact factor: 4.813

Review 3.  Physiology and pathophysiology of iron cardiomyopathy in thalassemia.

Authors:  John C Wood; Cathleen Enriquez; Nilesh Ghugre; Maya Otto-Duessel; Michelle Aguilar; Marvin D Nelson; Rex Moats; Thomas D Coates
Journal:  Ann N Y Acad Sci       Date:  2005       Impact factor: 5.691

4.  Global vasomotor dysfunction and accelerated vascular aging in beta-thalassemia major.

Authors:  George Hahalis; Dimitrios T Kremastinos; George Terzis; Andreas P Kalogeropoulos; Athina Chrysanthopoulou; Marina Karakantza; Alexandra Kourakli; Stamatis Adamopoulos; Alexandros D Tselepis; Nikos Grapsas; Dimitrios Siablis; Nicholas C Zoumbos; Dimitrios Alexopoulos
Journal:  Atherosclerosis       Date:  2007-11-07       Impact factor: 5.162

5.  Vitamin D deficiency, cardiac iron and cardiac function in thalassaemia major.

Authors:  John C Wood; Susan Claster; Susan Carson; J D Menteer; Thomas Hofstra; Rachna Khanna; Thomas Coates
Journal:  Br J Haematol       Date:  2008-03-26       Impact factor: 6.998

6.  Nutritional deficiencies in iron overloaded patients with hemoglobinopathies.

Authors:  Susan Claster; John C Wood; Leila Noetzli; Susan M Carson; Thomas C Hofstra; Rachna Khanna; Thomas D Coates
Journal:  Am J Hematol       Date:  2009-06       Impact factor: 10.047

7.  Improvement of cardiac function in thalassemia major treated with L-carnitine.

Authors:  Amal El-Beshlawy; Lamis Ragab; Alia Abdel Fattah; Ilham Youssry Ibrahim; Mona Hamdy; Ali Makhlouf; Elie Aoun; Victor Hoffbrand; Ali Taher
Journal:  Acta Haematol       Date:  2004       Impact factor: 2.195

  7 in total
  16 in total

1.  Imaging and quantification of iron-oxide nanoparticles (IONP) using MP-RAGE and UTE based sequences.

Authors:  Wen Hong; Qun He; Shujuan Fan; Michael Carl; Hongda Shao; Jun Chen; Eric Y Chang; Jiang Du
Journal:  Magn Reson Med       Date:  2016-08-06       Impact factor: 4.668

2.  Cardioprotective effects of iron chelator HAPI and ROS-activated boronate prochelator BHAPI against catecholamine-induced oxidative cellular injury.

Authors:  Pavlína Hašková; Hana Jansová; Jan Bureš; Miloslav Macháček; Anna Jirkovská; Katherine J Franz; Petra Kovaříková; Tomáš Šimůnek
Journal:  Toxicology       Date:  2016-10-12       Impact factor: 4.221

3.  The effect of metoprolol succinate on the cardiac function of patients with thalassaemia cardiomyopathy: a double-blind randomised study.

Authors:  Javad Kojury; Abdolali Zolghadrasli; Mehran Karimi; Mohammad Ali Babaee Beighi; Soha Namazi
Journal:  Heart Asia       Date:  2014-04-17

4.  Ischemia-modified albumin as a marker of vascular dysfunction and subclinical atherosclerosis in β-thalassemia major.

Authors:  Amira Abdel Moneam Adly; Nayera Hazaa Khalil ElSherif; Eman Abdel Rahman Ismail; Yosra Abdelzaher Ibrahim; Gamal Niazi; Sara Hamed Elmetwally
Journal:  Redox Rep       Date:  2017-03-13       Impact factor: 4.412

5.  Early detection of ventricular dysfunction by tissue Doppler echocardiography related to cardiac iron overload in patients with thalassemia.

Authors:  Suchaya Silvilairat; Pimlak Charoenkwan; Suwit Saekho; Adisak Tantiworawit; Somdet Srichairatanakool
Journal:  Int J Cardiovasc Imaging       Date:  2020-07-29       Impact factor: 2.357

Review 6.  Cardiac complications in beta-thalassemia: From mice to men.

Authors:  Sirinart Kumfu; Suthat Fucharoen; Siriporn C Chattipakorn; Nipon Chattipakorn
Journal:  Exp Biol Med (Maywood)       Date:  2017-05-09

7.  Pulmonary hypertension in well-transfused thalassemia major patients.

Authors:  Antonella Meloni; Jon Detterich; Alessia Pepe; Paul Harmatz; Tom D Coates; John C Wood
Journal:  Blood Cells Mol Dis       Date:  2014-11-24       Impact factor: 3.039

8.  A significant proportion of thalassemia major patients have adrenal insufficiency detectable on provocative testing.

Authors:  Karen E Huang; Steven D Mittelman; Thomas D Coates; Mitchell E Geffner; John C Wood
Journal:  J Pediatr Hematol Oncol       Date:  2015-01       Impact factor: 1.289

9.  Association between vitamin D levels and left ventricular function and NT-proBNP levels among thalassemia major children with iron overload.

Authors:  Leny Ambarwati; Sri Endah Rahayuningsih; Budi Setiabudiawan
Journal:  Ann Pediatr Cardiol       Date:  2016 May-Aug

10.  Clinical Manifestations of β-Thalassemia Major in Two Different Altitudes; Bushehr and Shahrekord.

Authors:  Mohammad Reza Ravanbod; Ali Movahed; Afshin Ostovar; Ali Hajigholami; Gholamreza Khamisipour; Shokrollah Farrokhi; Hossein Darabi; Yasaman Khosravi; Mohammad Kazzem Gheybi
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2016-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.